These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 33345392)
21. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1. Sipley JD; Alexander DS; Testa JE; Quigley JP Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324 [TBL] [Abstract][Full Text] [Related]
22. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. Lin Z; Jiang L; Yuan C; Jensen JK; Zhang X; Luo Z; Furie BC; Furie B; Andreasen PA; Huang M J Biol Chem; 2011 Mar; 286(9):7027-32. PubMed ID: 21199867 [TBL] [Abstract][Full Text] [Related]
24. Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes. Thompson LC; Goswami S; Peterson CB Protein Sci; 2011 Feb; 20(2):366-78. PubMed ID: 21280128 [TBL] [Abstract][Full Text] [Related]
25. High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor-related protein 1 requires lysines 80, 88, and 207. Migliorini M; Li SH; Zhou A; Emal CD; Lawrence DA; Strickland DK J Biol Chem; 2020 Jan; 295(1):212-222. PubMed ID: 31792055 [TBL] [Abstract][Full Text] [Related]
26. A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1. D'Amico S; Martial JA; Struman I FEBS Lett; 2012 Mar; 586(6):686-92. PubMed ID: 22449964 [TBL] [Abstract][Full Text] [Related]
27. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis. Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948 [TBL] [Abstract][Full Text] [Related]
28. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop. Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954 [TBL] [Abstract][Full Text] [Related]
30. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1. Gils A; Declerck PJ J Biol Chem; 1997 May; 272(19):12662-6. PubMed ID: 9139722 [TBL] [Abstract][Full Text] [Related]
31. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1. Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886 [TBL] [Abstract][Full Text] [Related]
32. A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product. Mulligan-Kehoe MJ; Wagner R; Wieland C; Powell R J Biol Chem; 2001 Mar; 276(11):8588-96. PubMed ID: 11113116 [TBL] [Abstract][Full Text] [Related]
33. Latency transition of plasminogen activator inhibitor type 1 is evolutionarily conserved. Jendroszek A; Sønnichsen MS; Muñoz AC; Leyman K; Christensen A; Petersen SV; Wang T; Bendixen C; Panitz F; Andreasen PA; Jensen JK Thromb Haemost; 2017 Aug; 117(9):1688-1699. PubMed ID: 28771275 [TBL] [Abstract][Full Text] [Related]
34. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor. Lijnen HR; De Cock F; Collen D Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373 [TBL] [Abstract][Full Text] [Related]
35. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Gils A; Knockaert I; Declerck PJ Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525 [TBL] [Abstract][Full Text] [Related]
36. Identification of a PAI-1-binding site within an intrinsically disordered region of vitronectin. Chu Y; Bucci JC; Peterson CB Protein Sci; 2020 Feb; 29(2):494-508. PubMed ID: 31682300 [TBL] [Abstract][Full Text] [Related]
37. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700 [TBL] [Abstract][Full Text] [Related]
38. Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. Jensen JK; Thompson LC; Bucci JC; Nissen P; Gettins PG; Peterson CB; Andreasen PA; Morth JP J Biol Chem; 2011 Aug; 286(34):29709-17. PubMed ID: 21697084 [TBL] [Abstract][Full Text] [Related]
39. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein. Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462 [TBL] [Abstract][Full Text] [Related]
40. A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. Mathiasen L; Dupont DM; Christensen A; Blouse GE; Jensen JK; Gils A; Declerck PJ; Wind T; Andreasen PA Mol Pharmacol; 2008 Sep; 74(3):641-53. PubMed ID: 18559377 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]